Ensysce Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ensysce Biosciences sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Ensysce Biosciences: 9 sponsored US clinical trials, 2 recruiting.

Ensysce Biosciences sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Postoperative Pain, Acute, with 1 trials.

Top-decile sponsor footprint

Ensysce Biosciences ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)

NCT06602271
RECRUITING Phase 1

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793
COMPLETED Phase 2

Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)

NCT06629402
COMPLETED Phase 1

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
COMPLETED Phase 1

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
COMPLETED Phase 1

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
COMPLETED Phase 1

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

NCT05043766
COMPLETED Phase 1

Oral Nafamostat in Healthy Volunteers (NAF-101)

NCT04406415
COMPLETED Phase 1

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

NCT02454712

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 1

Therapeutic Areas

Postoperative Pain, Acute 1
Acute Pain 1
Pharmacokinetics 1

What is open in the Ensysce Biosciences pipeline

2 recruiting of 9 indexed (22% open); 7 completed (78%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Postoperative Pain, Acute (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ensysce Biosciences: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

Ensysce Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share Ensysce Biosciences4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterHarvard University Faculty of Medicine
Ensysce Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ensysce Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ensysce Biosciences page

9 registered trials is a research-attention snapshot, not an endorsement of Ensysce Biosciences or any single study.

  • 2 of Ensysce Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Postoperative Pain, Acute is the condition Ensysce Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Postoperative Pain, Acute trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ensysce Biosciences pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.